Autolus Therapeutics announces acceptance of Biologics License Application for obecabtagene autoleucel (obe-cel) as a potential treatment for relapsed/refractory Adult B-cell Acute Lymphoblastic Leukemia (ALL)
22 janv. 2024 07h00 HE
|
Autolus Therapeutics plc
Autolus Therapeutics announces acceptance of BLA for obe-cel as a potential treatment for relapsed/refractory adult ALL